Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cardo wins auction for bankrupt Vertebron

This article was originally published in Clinica

Executive Summary

Orthopaedic expert Cardo Medical has boosted its product offering after purchasing bankrupt spinal implant firm Vertebron for $1.3m in cash. Vertebron (Stratford, Connecticut) manufactures and sells spinal implants for the lumbar and cervical spine, and for motion preservation technology. Its portfolio includes the PSS pedicle screw system, the SSP semi-constrained cervical plate, anterior cervical and posterior lumbar interbody fusion allografts and the Peek vertebral body replacement devices. According to Los Angeles, California-based Cardo, Vertebron generated around $11m in revenue in 2008. However, in April this year, Vertebron filed for bankruptcy. The acquisition follows an auction approved by the US Bankruptcy Court for the District of Connecticut.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT044451

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel